CNS Pharmaceuticals, Inc. (CNSP)

Market Cap	6.21M
Revenue (ttm)	n/a
Net Income (ttm)	-17.06M
Shares Out	57.49M
EPS (ttm)	-2.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,619,299
Open	0.105
Previous Close	0.110
Day's Range	0.101 - 0.120
52-Week Range	0.096 - 70.000
Beta	1.06
Analysts	Strong Buy
Price Target	0.50 (+362.96%)
Earnings Date	Nov 15, 2024

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceutical...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: CNSP
• Website: https://www.cnspharma.com

Analyst Forecast

According to one analyst, the rating for CNSP stock is "Strong Buy" and the 12-month stock price forecast is $0.5.

Price Target

$0.5

(362.96% upside)

Analyst Consensus: Strong Buy